The Evolving Type 2 Diabetes Market Access Landscape | Physician & Payer Forum | Brazil, Mexico and argentina | 2015
How Are Payer Strategies and Prescriber Preferences Shaping the Non-Insulin Treatment Algorithm?
Although a high opportunity market, the therapeutic space for type 2 diabetes (T2D) is set to become even more competitive with forthcoming entrants in Brazil, Mexico, and Argentina, such as long-acting GLP-1 receptor agonists and DPP-IV inhibitors, and the novel fixed-dose combinations of SGLT-2 inhibitors/metformin and of DPP-IV inhibitors/SGLT-2 inhibitors. Emerging therapies will likely be met with increased formulary and budgetary restrictions in these markets. As local and national governments have to bear the burden of treating a growing population with the disease, it is left to know if the treatment algorithm for T2D will advance as the treatment armamentarium evolves, or if it will stagnate even though more effective, yet more expensive therapies become available in these markets.
